ARS Pharmaceuticals (SPRY) Non-Current Debt (2021 - 2026)

ARS Pharmaceuticals (SPRY) reported Non-Current Debt of $96.5 million for Q1 2026, little changed sequentially from $96.4 million in Q4 2025.

ARS Pharmaceuticals (SPRY) Non-Current Debt (2021 - 2026) Analysis & Trends

ARS Pharmaceuticals (SPRY) has 3 years of Non-Current Debt data on file, last reported at $96.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Non-Current Debt changed N/A year-over-year to $96.5 million; the trailing twelve-month figure through Mar 2026 stood at $96.5 million (changed N/A YoY), and the FY2025 full-year result was $96.4 million, changed N/A from the prior year.
  • Non-Current Debt held at $96.5 million in Q1 2026, from $96.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $96.5 million in Q1 2026 to a low of $96.2 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 105.94 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 842.92 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 ARS Pharmaceuticals 595.78 Mn 394.81 Mn - 96.52 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 96.52 Mn
Dec 31, 2025 96.37 Mn
Sep 30, 2025 96.23 Mn
Dec 31, 2021 4.93 Mn